{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T21:10:02Z","timestamp":1750799402948,"version":"3.41.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T00:00:00Z","timestamp":1501804800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00280-017-3390-x","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T06:51:12Z","timestamp":1501829472000},"page":"673-684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition"],"prefix":"10.1007","volume":"80","author":[{"given":"Qiong","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Puhm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Freissmuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8857-2470","authenticated-orcid":false,"given":"Christian","family":"Nanoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,4]]},"reference":[{"key":"3390_CR1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0042-6822(88)90649-6","volume":"164","author":"Y Uehara","year":"1988","unstructured":"Uehara Y, Murakami Y, Mizuno S, Kawai S (1988) Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. Virology 164:294\u2013298","journal-title":"Virology"},{"key":"3390_CR2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","volume":"18","author":"L Neckers","year":"2012","unstructured":"Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: Are we there yet? Clin Cancer Res 18:64\u201376","journal-title":"Clin Cancer Res"},{"key":"3390_CR3","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-10-1927","volume":"17","author":"S Pacey","year":"2011","unstructured":"Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I (2011) A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 17:1561\u20131570","journal-title":"Clin Cancer Res"},{"key":"3390_CR4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10637-010-9493-4","volume":"30","author":"S Pacey","year":"2012","unstructured":"Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, Owen K, Asad Y, Raynaud F, Walton M, Judson I, Workman P, Eisen T (2012) A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs 30:341\u2013349","journal-title":"Invest New Drugs"},{"key":"3390_CR5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00280-011-1789-3","volume":"69","author":"G Iyer","year":"2012","unstructured":"Iyer G, Morris MJ, Rathkopf D, Slovin SF, Steers M, Larson SM, Schwartz LH, Curley T, DeLaCruz A, Ye Q, Heller G, Egorin MJ, Ivy SP, Rosen N, Scher HI, Solit DB (2012) A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol 69:1089\u20131097","journal-title":"Cancer Chemother Pharmacol"},{"key":"3390_CR6","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.3109\/10428194.2012.760733","volume":"54","author":"AR Walker","year":"2013","unstructured":"Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W (2013) Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 54:1996\u20132002","journal-title":"Leuk Lymphoma"},{"key":"3390_CR7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.urology.2011.04.041","volume":"78","author":"WK Oh","year":"2011","unstructured":"Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW (2011) Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology 78:626\u2013630","journal-title":"Urology"},{"key":"3390_CR8","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1158\/1078-0432.CCR-11-0821","volume":"17","author":"A Rajan","year":"2011","unstructured":"Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannargudi B, Figg WD, Houk BE, Shnaidman M, Brega N, Giaccone G (2011) A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 17:6831\u20136839","journal-title":"Clin Cancer Res"},{"key":"3390_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1471240713152","author":"JW Goldman","year":"2013","unstructured":"Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W, Inoue T, Rosen LS (2013) A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer. doi: 10.1186\/1471240713152","journal-title":"BMC Cancer"},{"key":"3390_CR10","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/annonc\/mdv031","volume":"26","author":"N Isambert","year":"2015","unstructured":"Isambert N, Delord JP, Soria JC, Hollebecque A, Gomez-Roca C, Purcea D, Rouits E, Belli R, Fumoleau P (2015) Debio0932, a second-generation oral heat shock protein(HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase. Ann Oncol 26:1005\u20131011","journal-title":"Ann Oncol"},{"key":"3390_CR11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.2014.653","volume":"112","author":"A Spreafico","year":"2015","unstructured":"Spreafico A, Delord JP, De Mattos-Arruda L, Berge Y, Rodon J, Cottura E, Bedard PL, Akimov M, Lu H, Pain S, Kaag A, Siu LL, Cortes J (2015) A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br J Cancer 112:650\u2013659","journal-title":"Br J Cancer"},{"key":"3390_CR12","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1200\/JCO.2014.59.7328","volume":"33","author":"ML Johnson","year":"2015","unstructured":"Johnson ML, Yu HA, Hart EM, Weitner BB, Rademaker AW, Patel JD, Kris MG, Riely GJ (2015) Phase I\/II Study of HSP90 inhibitor AUY922 and erlotinib for EGFR-Mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 33:1666\u20131673","journal-title":"J Clin Oncol"},{"key":"3390_CR13","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s10637-015-0255-1","volume":"33","author":"K Do","year":"2015","unstructured":"Do K, Speranza G, Chang LC, Polley EC, Bishop R, Zhu W, Trepel JB, Lee S, Lee MJ, Kinders RJ, Phillips L, Collins J, Lyons J, Jeong W, Antony R, Chen AP, Neckers L, Doroshow JH, Kummar S (2015) Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors. Invest New Drugs 33:921\u2013930","journal-title":"Invest New Drugs"},{"key":"3390_CR14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10637-015-0307-6","volume":"34","author":"MK Thakur","year":"2016","unstructured":"Thakur MK, Heilbrun LK, Sheng S, Stein M, Liu G, Antonarakis ES, Vaishampayan U, Dzinic SH, Li X, Freeman S, Smith D, Heath EI (2016) A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Invest New Drugs 34:112\u2013118","journal-title":"Invest New Drugs"},{"key":"3390_CR15","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bbamcr.2010.11.020","volume":"1813","author":"CM Filipeanu","year":"2011","unstructured":"Filipeanu CM, de Vries R, Danser AH, Kapusta DR (2011) Modulation of \u03b1(2C) adrenergic receptor temperature-sensitive trafficking by HSP90. Biochim Biophys Acta 1813:346\u2013357","journal-title":"Biochim Biophys Acta"},{"key":"3390_CR16","doi-asserted-by":"crossref","first-page":"28831","DOI":"10.1074\/jbc.M113.464776","volume":"288","author":"C Bergmayr","year":"2013","unstructured":"Bergmayr C, Thurner P, Keuerleber S, Kudlacek O, Nanoff C, Freissmuth M, Gruber CW (2013) Recruitment of a cytoplasmic chaperone relay by the A2A adenosine receptor. J Biol Chem 288:28831\u201328844","journal-title":"J Biol Chem"},{"key":"3390_CR17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0076-6879(94)38005-8","volume":"238","author":"R Johnson","year":"1994","unstructured":"Johnson R, Alvarez R, Salomon Y (1994) Determination of adenylyl cyclase catalytic activity by use of single and double column procedures. Methods Enzymol 238:31\u201356","journal-title":"Methods Enzymol"},{"key":"3390_CR18","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1210\/endo-122-4-1328","volume":"122","author":"AJ Marchingo","year":"1988","unstructured":"Marchingo AJ, Abrahams JM, Woodcock EA, Smith AI, Mendelsohn FA, Johnston CI (1988) Properties of [3H]1-desamino-8-d-arginine vasopressin as a radioligand for vasopressin V2-receptors in rat kidney. Endocrinology 122:1328\u20131336","journal-title":"Endocrinology"},{"key":"3390_CR19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jmb.2007.06.065","volume":"372","author":"SC Onuoha","year":"2007","unstructured":"Onuoha SC, Mukund SR, Coulstock ET, Sengerov\u00e0 B, Shaw J, McLaughlin SH, Jackson SE (2007) Mechanistic studies on Hsp90 inhibition by ansamycin derivatives. J Mol Biol 372:287\u2013297","journal-title":"J Mol Biol"},{"key":"3390_CR20","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0022-3565(25)20399-8","volume":"258","author":"S Caltabiano","year":"1991","unstructured":"Caltabiano S, Kinter LB (1991) Upregulation of renal adenylate cyclase-coupled vasopressin receptors after chronic administration of vasopressin antagonists to rats. J Pharmacol Exp Ther 258:1046\u20131056","journal-title":"J Pharmacol Exp Ther"},{"key":"3390_CR21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1681\/ASN.2005080854","volume":"17","author":"V Bernier","year":"2006","unstructured":"Bernier V, Morello JP, Zarruk A, Debrand N, Salahpour A, Lonergan M, Arthus MF, Laperri\u00e8re A, Brouard R, Bouvier M, Bichet DG (2006) Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 17:232\u2013243","journal-title":"J Am Soc Nephrol"},{"key":"3390_CR22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fphar.2016.00023","volume":"7","author":"T Vuki\u0107evi\u0107","year":"2016","unstructured":"Vuki\u0107evi\u0107 T, Schulz M, Faust D, Klussmann E (2016) The trafficking of the water channel aquaporin-2 in renal principal cells\u2014a potential target for pharmacological intervention in cardiovascular diseases. Front Pharmacol 7:23","journal-title":"Front Pharmacol"},{"key":"3390_CR23","doi-asserted-by":"crossref","first-page":"8397","DOI":"10.1073\/pnas.1509565112","volume":"112","author":"M Gao","year":"2015","unstructured":"Gao M, Cao R, Du S, Jia X, Zheng S, Huang S, Han Q, Liu J, Zhang X, Miao Y, Kang J, Gustafsson J\u00c5, Guan Y (2015) Disruption of prostaglandin E2 receptor EP4 impairs urinary concentration via decreasing aquaporin 2 in renal collecting ducts. Proc Natl Acad Sci USA 112:8397\u20138402","journal-title":"Proc Natl Acad Sci USA"},{"key":"3390_CR24","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1158\/0008-5472.CAN-07-5256","volume":"68","author":"SA Eccles","year":"2008","unstructured":"Eccles SA, Massey A, Raynaud FI et al (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68:2850\u20132860","journal-title":"Cancer Res"},{"key":"3390_CR25","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1111\/bph.13520","volume":"173","author":"T Hosoi","year":"2016","unstructured":"Hosoi T, Kohda T, Matsuzaki S, Ishiguchi M, Kuwamura A, Akita T, Tanaka J, Ozawa K (2016) Key role if heat shock protein 90 in leptin-induced STAT3 activation and feeding regulation. Br J Pharmacol 173:2434\u20132445","journal-title":"Br J Pharmacol"},{"key":"3390_CR26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1021\/jm980403y","volume":"42","author":"SM Roe","year":"1999","unstructured":"Roe SM, Prodromou C, O\u2019Brien R, Ladbury JE, Piper PW, Pearl LH (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42:260\u2013266","journal-title":"J Med Chem"},{"key":"3390_CR27","doi-asserted-by":"crossref","first-page":"13124","DOI":"10.1074\/jbc.M113.455394","volume":"288","author":"BF Donnelly","year":"2013","unstructured":"Donnelly BF, Needham PG, Snyder AC, Roy A, Khadem S, Brodsky JL, Subramanya AR (2013) Hsp70 and Hsp90 multichaperone complexes sequentially regulate thiazide-sensitive cotransporter endoplasmic reticulum-associated degradation and biogenesis. J Biol Chem 288:13124\u201313135","journal-title":"J Biol Chem"},{"key":"3390_CR28","doi-asserted-by":"crossref","first-page":"28987","DOI":"10.1074\/jbc.M114.595090","volume":"289","author":"A El-Kasaby","year":"2014","unstructured":"El-Kasaby A, Koban F, Sitte HH, Freissmuth M, Sucic S (2014) A cytosolic relay of heat shock proteins HSP70-1A and HSP90\u03b2 monitors the folding trajectory of the serotonin transporter. J Biol Chem 289:28987\u201329000","journal-title":"J Biol Chem"},{"key":"3390_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-94-007-4765-4_1","volume":"63","author":"C Nanoff","year":"2012","unstructured":"Nanoff C, Freissmuth M (2012) ER-bound steps in the biosynthesis of G protein-coupled receptors. Subcell Biochem 63:1\u201321","journal-title":"Subcell Biochem"},{"key":"3390_CR30","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1124\/mol.107.036566","volume":"72","author":"F He","year":"2007","unstructured":"He F, Qiao ZH, Cai J, Pierce W, He DC, Song ZH (2007) Involvement of the 90-kDa heat shock protein (Hsp-90) in CB2 cannabinoid receptor-mediated cell migration: a new role of Hsp-90 in migration and signaling of a G protein-coupled receptor. Mol Pharmacol 72:1289\u20131300","journal-title":"Mol Pharmacol"},{"key":"3390_CR31","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1681\/ASN.2015080903","volume":"27","author":"PW Cheung","year":"2016","unstructured":"Cheung PW, Nomura N, Nair AV, Pathomthongtaweechai N, Ueberdiek L, Lu HA, Brown D, Bouley R (2016) EGF receptor inhibition by erlotinib increases aquaporin 2-mediated renal water reabsorption. J Am Soc Nephrol 27:3105\u20133116","journal-title":"J Am Soc Nephrol"},{"key":"3390_CR32","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1681\/ASN.2016101139","volume":"28","author":"EJ Hoorn","year":"2017","unstructured":"Hoorn EJ, Zietse R (2017) Diagnosis and treatment of hyponatremia: compilation of the guidelines. J Am Soc Nephrol 28:1340\u20131349","journal-title":"J Am Soc Nephrol"},{"key":"3390_CR33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fonc.2017.00011","volume":"7","author":"M Pifano","year":"2017","unstructured":"Pifano M, Garona J, Capobianco CS, Gonzalez N, Alonso DF, Ripoll GV (2017) Peptide agonists of vasopressin V2 receptor reduce expression of neuroendocrine markers and tumor growth in human lung and prostate tumor cells. Front Oncol 7:11","journal-title":"Front Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3390-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3390-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3390-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T20:29:22Z","timestamp":1750796962000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3390-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["3390"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3390-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2017,8,4]]}}}